Scholars@Duke publication: CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy.

CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy.

Publication , Journal Article

Henrich, TJ; Hanhauser, E; Harrison, LJ; Palmer, CD; Romero-Tejeda, M; Jost, S; Bosch, RJ; Kuritzkes, DR

Published in: J Infect Dis

March 1, 2016

Published version (DOI) Open Access Copy (Duke) Link to item

We conducted a case-controlled study of the associations of CCR5-Δ32 heterozygosity with human immunodeficiency virus type 1 (HIV-1) reservoir size, lymphocyte activation, and CCR5 expression in 114 CCR5(Δ32/WT) and 177 wild-type CCR5 AIDS Clinical Trials Group participants receiving suppressive antiretroviral therapy. Overall, no significant differences were found between groups for any of these parameters. However, higher levels of CCR5 expression correlated with lower amounts of cell-associated HIV-1 RNA. The relationship between CCR5-Δ32 heterozygosity, CCR5 expression, and markers of HIV-1 persistence is likely to be complex and may be influenced by factors such as the duration of ART.

Duke Scholars

Author Stephanie Rachel Jost Surgery, Surgical Sciences

Altmetric Attention Stats

Dimensions Citation Stats

Published In

J Infect Dis

DOI

10.1093/infdis/jiv504

EISSN

1537-6613

Publication Date

March 1, 2016

Volume

213

Issue

Start / End Page

766 / 770

Location

United States

Related Subject Headings

T-Lymphocytes
Receptors, CCR5
RNA, Viral
Microbiology
Male
Lymphocyte Activation
Humans
HIV-1
HIV Infections
Genetic Predisposition to Disease

Citation

APA

Chicago

ICMJE

MLA

NLM

Henrich, T. J., Hanhauser, E., Harrison, L. J., Palmer, C. D., Romero-Tejeda, M., Jost, S., … Kuritzkes, D. R. (2016). CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy. J Infect Dis, 213(5), 766–770. https://doi.org/10.1093/infdis/jiv504

Henrich, Timothy J., Emily Hanhauser, Linda J. Harrison, Christine D. Palmer, Marisol Romero-Tejeda, Stephanie Jost, Ronald J. Bosch, and Daniel R. Kuritzkes. “CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy.” J Infect Dis 213, no. 5 (March 1, 2016): 766–70. https://doi.org/10.1093/infdis/jiv504.

Henrich TJ, Hanhauser E, Harrison LJ, Palmer CD, Romero-Tejeda M, Jost S, et al. CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy. J Infect Dis. 2016 Mar 1;213(5):766–70.

Henrich, Timothy J., et al. “CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy.” J Infect Dis, vol. 213, no. 5, Mar. 2016, pp. 766–70. Pubmed, doi:10.1093/infdis/jiv504.

Henrich TJ, Hanhauser E, Harrison LJ, Palmer CD, Romero-Tejeda M, Jost S, Bosch RJ, Kuritzkes DR. CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy. J Infect Dis. 2016 Mar 1;213(5):766–770.